NASDAQ: NVTS) Surges on NVIDIA Deal - SNYR, VIGL, XAGE Lead $2 Stock Watch Now, More Inside" src="https://www.abnewswire.com/upload/2025/05/1747919635.jpg" alt="Navitas (NASDAQ: NVTS) Surges on NVIDIA Deal - SNYR, VIGL, XAGE Lead $2 Stock Watch Now, More Inside" width="225" height="225">A wave of high-impact announcements is fueling explosive momentum across tech and healthcare stocks. From AI infrastructure to biotech M&A and consumer health expansion, investors are turning to breakout companies under $10 poised for rapid upside.
Top Tier $2 Stocks to Watch
Navitas Semiconductor (NASDAQ: NVTS) lit up after-hours trading with a major announcement: a partnership with NVIDIA (NASDAQ: NVDA) to power next-gen 800V HVDC data center infrastructure. Navitas' GaNFast™ and GeneSiC™ chips will support NVIDIA’s 1MW+ Kyber rack-scale systems, enabling next-gen GPUs like Rubin Ultra while cutting copper use by 45%. The deal cements Navitas as a cornerstone of future AI computing infrastructure.
Vigil Neuroscience (NASDAQ: VIGL) surged after Sanofi (NASDAQ: SNY) agreed to acquire the company for $8.00 per share in cash, plus a $2.00 CVR tied to commercial sales of VG-3927, a Phase 2-ready Alzheimer’s therapy. The deal values Vigil at $600 million, reinforcing the biotech M&A boom and clinical-stage upside.
Longevity Health Holdings (NASDAQ: XAGE) grabbed headlines with Nasdaq’s approval to maintain its listing during its upcoming merger with 20/20 BioLabs, a move to form a leader in regenerative bio-aesthetics, diagnostics, and longevity nutrition. The deal is expected to complete by September 2, 2025.
Synergy CHC Corp. (NASDAQ: SNYR) is attracting analyst and investor attention for its strong Q1 performance across its wellness brands FOCUSfactor and Flat Tummy. Roth Capital initiated coverage with a Buy rating and a $10 price target in April 2025, citing strong fundamentals and global expansion potential. With consumer health demand soaring, SNYR is positioned to scale aggressively. See Report Now!
Momentum Stocks on the Move Under $2: Tech, Health, AI, Chips, Signals, Etc.
As M&A and infrastructure breakthroughs ignite market momentum, investors are zeroing in on these emerging stocks under the $2 range in themes like AI, semiconductors, and digital health that collide with bullish technical setups and emerging catalysts:
- MicroAlgo Inc. (NASDAQ: MLGO) – Leading the charge in quantum machine learning, MLGO is developing next-gen algorithms that enhance model training speed and predictive accuracy through quantum parallelism. As AI complexity grows, so does the demand for scalable, accelerated compute.
- Peraso Inc. (NASDAQ: PRSO) – With over 2 million mmWave chips shipped, Peraso is emerging as a key enabler of high-speed wireless connectivity for defense, drones, wearables, and AR/VR. Backed by tailwinds from the $42.45B BEAD Act and the $280B CHIPS Act, PRSO is well-positioned for a federal infrastructure-driven breakout.
- Health In Tech Inc. (NASDAQ: HIT) – A rising force in insuretech, HIT leverages AI-powered, real-time underwriting platforms to streamline healthcare insurance delivery. Its scalable SaaS ecosystem is gaining traction with brokers and enterprise partners across the U.S.
With Navitas' (NVTS) after-hours surge, Vigil’s (VIGL) $600M biotech buyout, XAGE's (XAGE) Nasdaq merger greenlight, and Synergy’s’ (SNYR) Buy rating and $10 target from Roth Capital, momentum is accelerating across AI, biotech, and health sectors. As institutional and retail investors hunt for value-driven innovation, these trending tickers are well-positioned to lead the charge through Q2 and beyond.
A powerful surge of market-moving news is energizing select tech and healthcare stocks trading under $10. From high-voltage AI infrastructure to billion-dollar biotech M&A and explosive growth in consumer wellness, savvy investors are rotating into undervalued breakout candidates poised for outsized upside.
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.
Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com
